Navigation Links
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
Date:5/8/2009

EMERYVILLE, Calif., May 8 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced financial results for the three-month and nine-month periods ended March 31, 2009.

Revenues for the third quarter of fiscal 2009 were $3.0 million compared to $3.7 million for the third quarter of fiscal 2008. Research and development expenses were $1.9 million for the three months ended March 31, 2009 compared to $5.9 million for the three months ended March 31, 2008. The lower research and development expenses for the 2009 quarter were primarily due to the termination of the Viprinex(TM) program for stroke following the interim analysis in December 2008. General and administrative expenses were $1.4 million for the three months ended March 31, 2009 compared to $1.8 million for the three months ended March 31, 2008. During the third quarter of fiscal 2009, the Company terminated the employment of approximately 75% of its workforce, and the employee termination costs are included in the operating expenses for the 2009 period.

The net loss for the third quarter of fiscal 2009 was $0.4 million, or $0.02 per share, compared to a net loss of $5.1 million, or $0.19 per share, for the third quarter of fiscal 2008.

Revenues for the first nine months of fiscal 2009 were $10.1 million compared to revenues of $11.2 million for the same period of fiscal 2008. Research and development expenses were $17.7 million for the nine months ended March 31, 2009 compared to $18.8 million for the nine months ended March 31, 2008. General and administrative expenses were $4.0 million for the nine months ended March 31, 2009 compared to $5.3 million for the nine months ended March 31, 2008. The net loss for the nine months ended March 31, 2009 was $11.0 million, or $0.41 per share, compared to a net loss of $12.9
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
2. Neurobiological Technologies Reports Second Quarter Financial Results
3. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Neurobiological Technologies Reports Going Concern Qualification
8. Steven H. Kane Appointed as President and Chief Executive Officer of Patient Safety Technologies, Inc.
9. Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009
10. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
11. Greenway Medical Technologies PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...
(Date:6/19/2013)... is available in Spanish . ... neglected diseases, it goes by the name of the 10/90 ... devoted to conditions that accounted for 90 per cent of ... that the Drugs for Neglected Diseases initiative (DNDi) came into ... organization has been granted the BBVA Foundation Frontiers of Knowledge ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 ... of neurologists, neurosurgeons, psychiatrists and urologists with specialists ... The team works with patients and their family ... overall quality of life. Patients also have the ... trials and research. , “Movement disorders can be ...
(Date:6/19/2013)... June 19, 2013 North Carolina-based ... organizational changes to advance development of its technologies. ... “To support the advanced development of our product ... to the Company’s management structure and engaged industry ... Company announced that Michael Galiger will serve as ...
(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s indoor air ... kit at an exceptional price. The 5-2-1 Compressor Saver (also ... unit during start up, saving wear and tear on the ... out. , The 5-2-1 Compressor Saver works by ... power to start and drastically reduces the rush of heat ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3
... how the risk of death and heart attack can be ... that doubling the usual dose of an anti-clotting drug before ... in which a balloon-tipped catheter is threaded into an artery. ... and unblock the vessel. A small synthetic tube - stent ...
... has been found out that there is no association between ... -- and breast cancer. More than 43,000 women were studied ... had their average daily intake of acrylamide monitored. No evidence ... whose intake was higher was documented. Acrylamide was first discovered ...
... In the 83rd General Session of the International Association ... have presented the results of a study// that says ... bad breath. ,Oral bad odor or so called ... compounds like hydrogen sulfide. The study revealed that volunteers ...
... A new study has found out that depression has to ... anti-depressants // used to treat the same. The study was ... ,At first glance, results showed both the newer and older ... attack within the first month of being prescribed.The older class ...
... drug tezosentan did not improve worsening heart failure or prevent ... hopes. The above fact was found out in the largest ... was conducted to evaluate if something more could be done ... hospital discharge and prevent them from coming back. ,More ...
... help in controlling obesity. A new study coming up in ... that dietary calcium present in the yogurt has got anti-obesity ... and decrease in lipogenesis. ,The study took ... put on balanced deficit diets and the other was put ...
Cached Medicine News:
(Date:6/19/2013)... DIEGO , June 19, 2013   Nektar Therapeutics ... results from a human abuse liability (HAL) study for ... rate of entry into the brain.  This slow rate of ... to the abuse of and addiction to current opioid analgesics. ... NKTR-181 was rated similar to placebo in "drug liking" ...
(Date:6/19/2013)... -- Today leading web researchers Change Sciences Group ( ... sites for usability, engagement, and conversion. The rankings are ... compares how people experience sites with competitors and with ... top three performers are easier to use, more engaging ... have usability problems, lack aspects of design that compel ...
(Date:6/19/2013)... , June 19, 2013 Today ... solutions, introduced the next-generation of its Employer ... allows health plans to provide their employer groups ... health factors, medical and prescription drug claims, network ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2
... In 2009, more than 30 million people delayed seeking ... needed care due to the rising costs of healthcare in ... and cannot afford their prescriptions, medical treatment or even a ... dietary supplement brand with more than 10 years in the ...
... Jan. 24, 2011 NxStage Medical, Inc. (Nasdaq: ... products, today announced the addition of Nancy J. Ham ... of Jonathan T. Silverstein. Mr. Silverstein, General ... the Company,s 2008 financing, in which OrbiMed was the ...
Cached Medicine Technology:Codeco® Nutrilife Brings Hope to Hispanics Through Alternative Medicine 2NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein 2
... versatility, and environmental safety are ... LE-80 K Ultracentrifuge from Beckman ... Optima centrifugation technology, the LE-80 ... effectively provide advanced capability for ...
... With the ability to provide a simple, ... in lipemic samples), the Airfuge CLS delivers ... can be cleaned in 10 minutes, eliminating ... tabletop centrifuge: Reaches top speed in as ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... Microvolume technology , The ADVIA ... (as low as 2 L/test), reagent consumption ... consumption (25 L/hour) - thus maximizing management ... rapid, 3-second cycle and system throughput of ...
Medicine Products: